Verona Pharma PLC Holding(s) in Company (3390E)
May 05 2017 - 6:36AM
UK Regulatory
TIDMVRP
RNS Number : 3390E
Verona Pharma PLC
05 May 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------
1. Identity of the issuer or Verona Pharma plc
the underlying issuer
of existing shares to which
voting rights are
attached:
------------------------------------------------------------- ------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
---------------------------------------------------------------------------------------
An acquisition or disposal of voting rights x
----------------------------------------------------------------- --------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
----------------------------------------------------------------- --------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
----------------------------------------------------------------- --------------------
An event changing the breakdown of voting rights
----------------------------------------------------------------- --------------------
Other (please
specify):
--------------------------------------------------------- ------ --------------------
3. Full name of person(s) BioDiscovery 4 FPCI
subject to the
notification obligation:
----------------------------------------------------------- --------------------------
4. Full name of shareholder(s)
(if different from 3.):
----------------------------------------------------------- --------------------------
5. Date of the transaction 2 May 2017
and date on
which the threshold is
crossed or
reached:
----------------------------------------------------------- --------------------------
6. Date on which issuer 4 May 2017
notified:
----------------------------------------------------------- --------------------------
7. Threshold(s) that is/are 4.31% to 5.83%
crossed or
reached:
----------------------------------------------------------- --------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if
possible
using
the ISIN
CODE
----------- ---------------------------------- ---------------------------------------------------------------------
Number Number Number Number of voting % of voting
of of of shares rights rights
Shares Voting
Rights
----------- ---------------- ---------------- -------------- -------------------------- -------------------------
Direct Direct Indirect Direct Indirect
----------- ------------ ------------ -------------- ------------ ------------ ------------ -----------
Ordinary
Shares 2,212,033 2,212,033 5,767,585 5,767,585 5.83%
---------------- ---------------- -------------- ------------ ------------ ------------ -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument Period may be
acquired if
the
instrument
is
exercised/
converted.
--------------- -------------- -------------------------------- ---------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights
instrument period refers to
------------- -------------- -------------- ---------------- ---------------------------- -----------------------
Nominal Delta
------------- -------------- -------------- ---------------- ---------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------------------------------- -------------------------------------------------------------------
5,767,585 5.83%
------------------------------------------------- -------------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
--------------------------------------------------------------------------------
The voting rights are managed and controlled by Edmond
de Rothschild Investment Partners, acting in its capacity
of management company of BioDiscovery 4 FPCI.
Proxy Voting:
--------------------------------------------------------------------------------
10. Name of the proxy holder:
------------------------------------------------------------- -----------------
11. Number of voting rights proxy
holder will cease to hold:
------------------------------------------------------------- -----------------
12. Date on which proxy holder will
cease to hold voting rights:
------------------------------------------------------------- -----------------
13. Additional information:
------------------------------------------------------------- -----------------
14. Contact name: Naveed Siddiqi
Andrei Buzdugan
------------------------------------------------------------- -----------------
+33 698 661 203
15. Contact telephone number: +33 140 176 968
------------------------------------------------------------- -----------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUGUCWAUPMGUA
(END) Dow Jones Newswires
May 05, 2017 06:36 ET (10:36 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
